ライフサイエンスコーパス: prescriber

1 aused unnecessary concern among patients and prescribers.

2 eceived treatment from high-intensity opioid prescribers.

3 s who received treatment from high-intensity prescribers.

4 th systems, heightens the challenge faced by prescribers.

5 h industry were similar to those reported by prescribers.

6 chart review and interview with patients and prescribers.

7 ate more effective education of these future prescribers.

8 nd agreement and participation by individual prescribers.

9 pulations having different patterns of using prescribers.

10 ed 32 opioid prescriptions from 10 different prescribers.

11 alendar quarter); 8% had four or more opioid prescribers; 5% had prescriptions yielding a daily MED o

12 ely between low-intensity and high-intensity prescribers (7.3% vs. 24.1%).

13 being high-intensity or low-intensity opioid prescribers according to relative quartiles of prescribi

14 nd obtain patient signatures on the "Patient-Prescriber Acknowledgement Form." A single, national, vo

15 than among patients treated by low-intensity prescribers (adjusted odds ratio, 1.30; 95% confidence i

16 Informed consent and patient-prescriber agreements are important strategies to ensure

17 fied if they saw the nurse as diagnostician, prescriber and medical manager of the condition.

18 ts who received treatment from low-intensity prescribers and 161,951 patients who received treatment

19 Strategies that include frontline prescribers and other unit-based healthcare providers ha

20 ent, the majority of analgesics available to prescribers and patients are based on mechanistic classe

21 Randomised assignments were concealed from prescribers and patients but not masked as the test resu

22 Prescribers and patients should consider the potential c

23 Use of multiple prescribers and pharmacies is a means by which some indi

24 independently associated with the number of prescribers and pharmacies that individuals used for pre

25 d physician availability) with the number of prescribers and the number of pharmacies that an individ

26 nd surgeons were associated with use of more prescribers and/or more pharmacies for obtaining prescri

27 ionship with staff (especially the physician-prescriber), and the patient's admission experience (max

28 alcohol use, 33 (94%) required a specialist prescriber, and 34 (97%) had no additional restrictions

29 can only be done safely if initiated by the prescriber, and in well-informed and prepared patients.

30 patents, promote sales, and advise patients, prescribers, and dispensers.

31 ulatory decision makers, including patients, prescribers, and payers, because regulatory trials do no

32 risk communication was sent directly to all prescribers, and specifically recommended review of all

33 Although rulings cited prescribers as the prime target of off-label promotion,

34 emains an important topic of concern for all prescribers as well as drug manufacturers.

35 analyzed using 2013 to 2015 Medicare Part D Prescriber Data.

36 de because of slips in attention, or because prescribers did not apply relevant rules.

37 Attorney General Consumer and Prescriber Education grant program, the Robert Wood John

38 Institute and Attorney General Consumer and Prescriber Education Program.

39 Besides prescriber education, policy makers may need to consider

40 A poor relationship with the prescriber, experience of coercion during admission, and

41 ducational interviews between counselors and prescribers from all departments to reinforce the princi

42 audit with feedback; however, engagement of prescribers has not been fully explored.

43 Prescribers identify with the clinical groups in which t

44 prevented, and communication with outpatient prescribers is vital.

45 product switches are likely to occur without prescriber knowledge and may pose a significant patient

46 ded the subset of adults (n = 1813) for whom prescriber knowledge, attitudes, and behavior survey dat

47 n and quality of care provided by low-volume prescribers (LVPs) based on available data sources in Ne

48 y 1, 2010, to December 31, 2012) linked with prescriber market data.

49 al need for opioids who use large numbers of prescribers may signal dangerously uncoordinated care.

50 ical situation requires a medication change, prescribers may want to take steps to optimize current m

51 Prescribers must understand the clinical outcomes of met

52 another, initiated outside the scope of the prescriber, must be avoided as they are unsafe.

53 promotional tactic was attempts to influence prescribers (n = 72, 97%), using print material (70/72,

54 companies lodged the majority of complaints (prescriber: n = 16, 22%, versus companies: n = 42, 57%).

55 of potentially serious adverse consequences, prescribers need to evaluate the evidence objectively to

56 Consequently, the FDA determined that prescribers of FMT must possess an approved investigatio

57 tering the order, who could then consult the prescriber on alternative therapies and implement more i

58 es; and more effectively educating patients, prescribers, payers, and policy makers about these choic

59 has become a source of concern for patients, prescribers, payers, and policy makers.

60 ns, infants and children </= 2 years of age, prescribers per capita, and females were more likely to

61 for inclusion were: Registered Nurses, nurse prescribers, Physician Assistants, pharmacists, dieticia

62 Analysis incorporating prescriber practice information found lower failure to r

63 ce of beneficiaries with four or more opioid prescribers, prescriptions yielding a daily morphine-equ

64 Secondary measures included spironolactone prescriber profiles and potassium monitoring practices.

65 hysician organizations in the development of prescriber profiling is directly relevant to the contemp

66 Medicare Part D 2013 prescriber public use file and summary file were used to

67 pective cost analysis of the Medicare Part D Prescriber Public Use File, which details annual drug ut

68 dicare and Medicaid Services Medicare Part D Prescriber Public Use Files for 2013, 2014, and 2015 wer

69 ptions written annually by ophthalmologists; prescriber rates compared with all prescriptions written

70 cluding refills, number of days' supply, and prescriber rates) for all participating ophthalmologists

71 Restricted access to opioids, prescriber restriction laws, and a low prevalence of mor

72 diates the relationship between race and the prescriber's opioid selection; and whether the chosen op

73 ce improvement initiatives should target all prescriber settings and not just behavioral health.

74 UK prescribers should be attentive to, and increasingly rep

75 Prescribers should be mindful of diabetes risks when tre

76 d with approval/abandonment including payor, prescriber specialty, pharmacy benefit manager, out-of-p

77 However, the initiating prescriber specialty-setting was not associated with lip

78 ted antipsychotic medication in a variety of prescriber specialty-settings: 24.3%, community mental h

79 Prescriber surveys were disseminated by neurocritical ca

80 her among patients treated by high-intensity prescribers than among patients treated by low-intensity

81 ) but rated their peers as more conservative prescribers than themselves (median, 3; IQR, 2 to 5).

82 s integrated into the workflow of nurses and prescribers that facilitate review of antibiotic use, an

83 thirds of states have restrictions based on prescriber type, and 88% include drug or alcohol use in

84 to liver disease staging, HIV co-infection, prescriber type, and drug or alcohol use across the Unit

85 ries: liver disease stage, HIV co-infection, prescriber type, and drug or alcohol use.

86 es were fibrosis stage, drug or alcohol use, prescriber type, and HIV co-infection restrictions.

87 The incidence rates of new prescriber use and new pharmacy use for opioid prescript

88 Males had a lower incidence rate of new prescriber use and new pharmacy use than females.

89 d treatment, perceived relationship with the prescriber, ward atmosphere, and admission experience.

90 similar dosages, regardless of whether their prescriber was a primary care physician or a psychiatris

91 CMHC (0.74 [0.64-0.85]) or if the initiating prescriber was a primary care practitioner (0.81 [0.66-1

92 ations who are vulnerable to infection, have prescribers who are often off-site, and have limited acc

93 We interviewed the prescribers who made 44 of these, and analysed our findi

94 predictors of premature discontinuation were prescriber, with patients of general practitioners demon

95 s treated by high-intensity or low-intensity prescribers, with adjustment for patient characteristics